Short Interest Coverage: Is Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) a Buy? The Stock Reported Less Sellers

November 24, 2016 - By Darrin Black   ·   0 Comments

Short Interest Coverage: Is Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) a Buy? The Stock Reported Less Sellers

The stock of Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) registered a decrease of 9.97% in short interest. ALDX’s total short interest was 30,700 shares in November as published by FINRA. Its down 9.97% from 34,100 shares, reported previously. With 44,400 shares average volume, it will take short sellers 1 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Incorporated’s float is 1.06%. The stock decreased 0.83% or $0.05 on November 23, hitting $5.95. About 21,283 shares traded hands. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has declined 0.17% since April 22, 2016 and is downtrending. It has underperformed by 5.58% the S&P500.

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The company has a market cap of $70.08 million. The Company’s principal activities include raising capital and research and development activities. It currently has negative earnings. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insitutional Activity: The institutional sentiment decreased to 1.14 in 2016 Q2. Its down 0.74, from 1.88 in 2016Q1. The ratio dived, as 4 funds sold all Aldeyra Therapeutics Inc shares owned while 4 reduced positions. 2 funds bought stakes while 13 increased positions. They now own 6.07 million shares or 40.87% more from 4.31 million shares in 2016Q1.
Blackrock Limited Liability Corp holds 0% or 2,978 shares in its portfolio. Moreover, Fny Managed Accounts Ltd Liability has 0% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 5,000 shares. Weiss Multi has invested 0.03% of its portfolio in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Dafna Mgmt Limited Liability has 0.01% invested in the company for 2,499 shares. Walleye Trading Limited Co has 1,400 shares for 0% of their US portfolio. Northern Trust holds 0% or 12,366 shares in its portfolio. Fmr Ltd has invested 0% of its portfolio in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Millennium Mgmt Ltd Liability accumulated 130,500 shares or 0% of the stock. Baker Bros Advsr Limited Partnership holds 142,000 shares or 0.01% of its portfolio. Moreover, Manufacturers Life The has 0% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 941 shares. Vanguard Group Incorporated last reported 125,125 shares in the company. The New York-based Morgan Stanley has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Savings Bank Of America Corporation De holds 0% of its portfolio in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 3,254 shares. Croft holds 0.02% of its portfolio in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 17,000 shares. The New York-based Deerfield Mngmt has invested 0.06% in Aldeyra Therapeutics Inc (NASDAQ:ALDX).

Aldeyra Therapeutics Inc (NASDAQ:ALDX) Ratings Coverage

Out of 3 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $18 is the highest target while $13 is the lowest. The $16.50 average target is 177.31% above today’s ($5.95) stock price. Aldeyra Therapeutics Inc has been the topic of 4 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, September 26 by H.C. Wainwright. The rating was initiated by Cowen & Co on Tuesday, September 8 with “Outperform”. Stifel Nicolaus initiated Aldeyra Therapeutics Inc (NASDAQ:ALDX) on Friday, July 1 with “Buy” rating.

ALDX Company Profile

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., incorporated on August 13, 2004, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Firm is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Firm has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes.

More news for Aldeyra Therapeutics Inc (NASDAQ:ALDX) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on May 09, 2014. 247Wallst.com‘s article titled: “Why Aldeyra Therapeutics Could Have Exponential Upside” and published on April 04, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>